TC
ABBV icon

TFR Capital’s AbbVie ABBV Stock Holding History

TFR Capital’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.81M Buy
17,516
+400
+2% +$88.7K 1.17% 23
2025
Q4 		$3.91M Buy
17,116
+717
+4% +$163K 1.3% 19
2025
Q3 		$3.8M Buy
16,399
+825
+5% +$168K 1.27% 18
2025
Q2 		$2.89M Buy
15,574
+352
+2% +$65.4K 1.05% 21
2025
Q1 		$3.19M Buy
15,222
+2,038
+15% +$396K 1.33% 19
2024
Q4 		$2.34M Buy
+13,184
New +$2.42M 1.16% 23

Other funds holding ABBV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

TFR Capital's ABBV Position: Q1 2026 in Review

TFR Capital increased its AbbVie (ABBV) stake by 2.3% in Q1 2026, buying an estimated $88.7K and bringing the position to 17,516 shares worth $3.81M. The position accounts for 1.17% of the portfolio, ranked #23.

TFR Capital first reported a position in ABBV in Q4 2024 and has held it in 6 quarters since. The position peaked at $3.91M in Q4 2025. 4,079 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • TFR Capital held 17,516 shares of AbbVie worth $3.81M as of Q1 2026.
  • TFR Capital bought 400 AbbVie shares in Q1 2026, an estimated $88.7K.
  • AbbVie made up 1.17% of TFR Capital's portfolio in Q1 2026, its #23 holding.
  • TFR Capital first reported a position in AbbVie in Q4 2024 and has held it in 6 quarters since.
  • TFR Capital's AbbVie position peaked at $3.91M in Q4 2025.
  • 4,079 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on TFR Capital's 13F filing for Q1 2026, filed 4 May 2026.